The journal Nature discusses California's CIRM
An article in the journal Nature contains the following text about Bob Klein, chairman of CIRM:
Yet many critics say that Klein and CIRM have failed to fully deliver. Despite promises that money borrowed from the state — at least $6 billion over ten years, when interest is factored in — would be returned through commercial spin-offs and savings to health care, the first marketable therapies have yet to materialize. Only two CIRM-funded projects have made it to early-stage clinical trials, and neither of these involves embryonic stem cells — the main impetus for launching the agency in the first place. The embryonic stem-cell clinical trials that have recently been approved in the United States are the product of privately funded research.
A comment to californiastemcellreport on 7 Dec. 2010:
Note the coverage in Nature of the situation at CIRM:
Stem cells: The impatient advocate [ Nature 468, 620-623 (2010) ]
Of the CIRM requirement -- a direct knowledge of bond financing. --, note the rather sad misunderstanding by CIRM of requirements for tax-exempt bonds, a mistake which cost California taxpayers quite a bit of money.
This is part of continued misunderstanding by CIRM of the role of intellectual property in a state-financed research venture, a matter which has also cost California taxpayers a bit of money.
**As noted of the Washington Redskins in the Haynesworth matter, what was CIRM thinking?
The [Scott] contract in retrospect is quite friendly, considering the signing the Washington Redskins made for DT Albert Haynesworth, signing him at 7-years for $100 million. What was Washington thinking? Haynesworth has had two good seasons (one of which being during a contract year), and he’s the same man who stomped on the face of an opponent in 2006.
Yet many critics say that Klein and CIRM have failed to fully deliver. Despite promises that money borrowed from the state — at least $6 billion over ten years, when interest is factored in — would be returned through commercial spin-offs and savings to health care, the first marketable therapies have yet to materialize. Only two CIRM-funded projects have made it to early-stage clinical trials, and neither of these involves embryonic stem cells — the main impetus for launching the agency in the first place. The embryonic stem-cell clinical trials that have recently been approved in the United States are the product of privately funded research.
A comment to californiastemcellreport on 7 Dec. 2010:
Note the coverage in Nature of the situation at CIRM:
Stem cells: The impatient advocate [ Nature 468, 620-623 (2010) ]
Of the CIRM requirement -- a direct knowledge of bond financing. --, note the rather sad misunderstanding by CIRM of requirements for tax-exempt bonds, a mistake which cost California taxpayers quite a bit of money.
This is part of continued misunderstanding by CIRM of the role of intellectual property in a state-financed research venture, a matter which has also cost California taxpayers a bit of money.
**As noted of the Washington Redskins in the Haynesworth matter, what was CIRM thinking?
The [Scott] contract in retrospect is quite friendly, considering the signing the Washington Redskins made for DT Albert Haynesworth, signing him at 7-years for $100 million. What was Washington thinking? Haynesworth has had two good seasons (one of which being during a contract year), and he’s the same man who stomped on the face of an opponent in 2006.
posted by Lawrence B. Ebert at 9:02 AM
0 Comments:
Post a Comment
<< Home